Astrana Health, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 12, 2024, the date of Astrana Health, Inc.'s 2024 Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes and the approval of a new equity incentive plan.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. This report focuses on corporate governance and equity plan approvals rather than financial performance.
Material Changes and Corporate Actions
- Equity Incentive Plan Approval: Stockholders approved the 2024 Equity Incentive Plan, replacing the 2015 Plan. The new plan authorizes up to 2,100,000 shares for awards including stock options, restricted shares, and stock appreciation rights. No further awards will be made under the 2015 Plan, though existing awards remain outstanding.
- Board Elections: Nine directors were elected to serve until the 2025 Annual Meeting. All nominees received significant majority support.
- Accounting Firm Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Executive Compensation: The compensation program for named executive officers was approved on an advisory, non-binding basis.
- Charter Amendment: An amendment to the Restated Certificate of Incorporation regarding officer exculpation under new Delaware law was approved.
Voting Results Summary
| Proposal | For Votes | Against Votes | Abstain |
|---|---|---|---|
| Election of Directors (Aggregate) | 336,352,965 | 6,013,947 | N/A |
| Ratification of Auditor | 41,792,861 | 463,866 | 80,430 |
| Advisory Vote on Compensation | 37,336,707 | 428,882 | 392,530 |
| Approval of 2024 Equity Plan | 37,131,279 | 666,874 | 359,966 |
| Officer Exculpation Amendment | 37,447,250 | 620,311 | 90,558 |
Note: 42,337,157 shares were present at the meeting, representing approximately 75.6% of outstanding eligible votes.
Outlook, Risks, and Contingencies
The filing does not contain specific forward-looking guidance, risk factors, or unusual items beyond the standard administrative details of the equity plan. The 2024 Plan will terminate on February 27, 2034, if not amended or terminated earlier by the Board.
Key Facts for Investor Verification
- Verify the specific terms of the 2024 Equity Incentive Plan in Exhibit 10.1 attached to this filing.
- Confirm the impact of the 2,100,000 share authorization on potential future dilution.
- Review the full list of elected directors and their biographies in the Definitive Proxy Statement filed on April 24, 2024.
- Check subsequent filings for the actual issuance of awards under the new 2024 Plan.